Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

February 25, 2021

Study Completion Date

March 22, 2021

Conditions

Healthy

Interventions

DRUG

Revemact

1 tablet contains 6 mg Ivermecin

DRUG

Stromectol (first dose)

2 tablet contain 6 mg Ivermecin

DRUG

Stromectol (second dose)

2 tablet contain 6 mg Ivermecin

Trial Locations (1)

Genuine Research Center GRC, Cairo